What is it about?
Although a short hydration protocol for cisplatin has been recently developed for use in lung cancer, this has yet to be established for gastric cancer.
Featured Image
Why is it important?
Although a short hydration method for cisplatin was developed for use in lung cancer, there has been no similar method established for use in gas- tric cancer. Since some gastric cancer patients have difficulty with oral intake, a method that can be used in these patients would be beneficial.
Perspectives
our current study was conducted in order to compare the ability of the conventional regimen (CV regimen) and the short hydration regi- men (SH regimen) to prevent the nephrotoxicity of the XPT therapy when used to treat gastric cancer.
Takeshi Aoyama
Gan Kenkyukai
Read the Original
This page is a summary of: Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer—a retrospective study, Journal of Chemotherapy, January 2020, Taylor & Francis,
DOI: 10.1080/1120009x.2020.1713507.
You can read the full text:
Contributors
The following have contributed to this page
